0M61.BE - Myomo Inc

Berlin - Berlin Delayed Price. Currency in EUR
0.5100
+0.0260 (+5.37%)
At close: 09:52PM CEST
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.4840
Open0.4780
Bid0.4720 x N/A
Ask0.5350 x N/A
Day's Range0.4660 - 0.5150
52 Week Range0.3420 - 2.2000
Volume4,000
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateAug 01, 2023 - Aug 07, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 0M61.BE

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Zacks

      Here's Why Myomo, Inc. (MYO) Is a Great 'Buy the Bottom' Stock Now

      Myomo, Inc. (MYO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

    • Zacks

      Myomo, Inc. (MYO) Reports Q1 Loss, Tops Revenue Estimates

      Myomo, Inc. (MYO) delivered earnings and revenue surprises of 26.67% and 3.51%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

    • Zacks

      Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Beat Estimates

      Supernus (SUPN) delivered earnings and revenue surprises of 141.67% and 8.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

    • Zacks

      Owens & Minor (OMI) Beats Q1 Earnings and Revenue Estimates

      Owens & Minor (OMI) delivered earnings and revenue surprises of 155.56% and 4.15%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

    • Business Wire

      Myomo to Report First Quarter Financial Results on May 10, 2023

      BOSTON, May 03, 2023--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months ended March 31, 2023 on May 10, 2023.

    • Business Wire

      Myomo Receives Technology License Fee Payment from China Joint Venture Company

      BOSTON, April 10, 2023--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces receipt of the final portion of the initial license fee under the Technology License Agreement with its joint venture company in China, Jiangxi Myomo Medical Assistive Appliance Co. Ltd. (the "JV Company").

    • The Wall Street Journal

      SVB Collapse Spurs Finance Executives to Re-Evaluate Cash Strategies

      Financial officers at companies with money held at Silicon Valley Bank are re-evaluating their cash-management strategies in the wake of the bank’s collapse, a reckoning that comes after many firms feared they also would go under without access to their funds.

    • Business Wire

      Myomo Makes NYSE American Section 610(b) Public Announcement

      BOSTON, March 15, 2023--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2022 filed on March 13, 2023 with the Securities and Exchange Commission, the audited financial statements for the year ended December 31, 2022 included in t

    • Insider Monkey

      Myomo, Inc. (AMEX:MYO) Q4 2022 Earnings Call Transcript

      Myomo, Inc. (AMEX:MYO) Q4 2022 Earnings Call Transcript March 13, 2023 Operator: Good morning, and welcome to the Myomo, Inc. Fourth Quarter and Full Year 2022 Earnings Conference Call. All participants will be in listen-only mode. After today’s presentation, there will be an opportunity to ask questions. Please note that this event is being recorded. […]

    • Business Wire

      Myomo Reports Fourth Quarter and Full Year 2022 Financial Results

      BOSTON, March 13, 2023--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and full year ended December, 31, 2022.

    • Business Wire

      Myomo to Report Fourth Quarter Financial Results on March 13, 2023

      BOSTON, March 07, 2023--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months and year ended December 31, 2022 on March 13, 2023 before the opening of the market.

    • Business Wire

      Myomo To Participate in the 35th Annual Roth Conference

      BOSTON, March 06, 2023--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces that management will presenting at the 35th Annual Roth Conference, March 13-14, 2023 at The Ritz-Carlton, Dana Point, Calif. David Henry, Myomo’s chief financial officer will participate in a "Fireside Chat" on Monday, March 13th at 1:30 p.m. PT and will be

    • Business Wire

      MyoPro Approved in Australia by National Disability Insurance Scheme

      BOSTON, February 06, 2023--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced that for the first time, the National Disability Insurance Scheme (NDIS) in Australia approved a MyoPro for a patient with a paralyzed arm. The NDIS aids over 500,000 Australians with disabilities through reimbursement for necessary services and support.

    • InvestorPlace

      7 Top Short-Squeeze Candidates to Watch in February

      While everyone knows that in order to have a market, there must be bulls and bears, that’s not going to stop people from attempting to garner intense profits from top short-squeeze candidates. To quickly summarize, shorting stocks involves borrowing shares to initiate the “negative” position. At some point, though, those borrowed shares must be returned. For the bears, they can be returned either at a profit or a loss. Now, in order to panic the bears into buying back their borrowed shares befor

    • Business Wire

      Myomo Appoints Yitzchak Jacobovitz to its Board of Directors

      BOSTON, January 30, 2023--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Yitzchak Jacobovitz as a Class II director effective January 27, 2023, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has six directors.

    • Business Wire

      Myomo Announces Closing of $6.5 Million Upsized Public Offering

      BOSTON, January 17, 2023--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the closing of its previously announced "best efforts" public offering of 20,000,000 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.325 per share for aggregate gross proceeds of approximately $6.5

    • Business Wire

      Myomo Announces Pricing of $6.5 Million Upsized Public Offering

      BOSTON, January 12, 2023--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the pricing of its "best efforts" public offering of 20,000,000 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.325 per share for aggregate gross proceeds of approximately $6.5 million, before dedu

    • Business Wire

      Myomo Announces Initiative to Reduce Cash Burn

      BOSTON, January 10, 2023--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced a reduction in force for the purpose of improving operating efficiency in its direct billing channel and reduce its cash burn. The action today involved the elimination of approximately 12% of its workforce, impacting employees in its call center and

    • Business Wire

      Myomo Provides Update on Progress to Obtain Medicare Part B Reimbursement for MyoPro

      BOSTON, December 07, 2022--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported progress and next steps in the process to obtain Medicare Part B reimbursement for the MyoPro® as a brace from the Centers for Medicare & Medicaid Services (CMS).

    • Business Wire

      Ruling by German Social Court Supports MyoPro Reimbursement by Nation’s Statutory Health Insurance System

      BOSTON, December 05, 2022--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that in an appeal before the Berlin-Brandenburg Regional Social Court (L 9 KR 210/21), the court confirmed that the MyoPro powered whole-arm orthosis is an orthopedic aid that serves to directly compensate for disabilities. As a result of this ruling

    • Insider Monkey

      10 Best Robotic Stocks Under $10

      In this article, we will be taking a look at the 10 best robotic stocks under $10. To skip our discussion on the robotics industry, you can go directly to the 5 Best Robotic Stocks Under $10. According to Statista, the size of the industrial robotics segment is expected to compound annually at an average […]

    • Zacks

      Myomo, Inc. (MYO) Reports Q3 Loss, Tops Revenue Estimates

      Myomo, Inc. (MYO) delivered earnings and revenue surprises of 14.89% and 4.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

    • Business Wire

      Myomo Reports Third Quarter 2022 Financial Results Featuring Strong Authorizations and Orders and Record Backlog

      BOSTON, November 10, 2022--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months ended September 30, 2022.

    • Zacks

      NuVasive (NUVA) Surpasses Q3 Earnings Estimates

      NuVasive (NUVA) delivered earnings and revenue surprises of 1.89% and 0.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

    • Business Wire

      Myomo to Report Third Quarter Financial Results on November 10, 2022

      BOSTON, November 03, 2022--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and nine months ended September 30, 2022 on November 10, 2022, after the market close.